Want to see JP:6090 full AI Analyst Report?
6090 Stock Chart & Stats
¥715.00
¥1.00(0.16%)
At close: 4:00 PM EST
¥715.00
¥1.00(0.16%)
Day’s Range― - ―
52-Week Range¥570.00 - ¥797.00
Previous CloseN/A
Volume5.70K
Average Volume (3M)10.25K
Market Cap
¥3.42B
Enterprise Value¥2.32B
Total Cash (Recent Filing)¥1.46B
Total Debt (Recent Filing)¥105.06M
Price to Earnings (P/E)26.8
Beta0.31
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.12%
Share Statistics
EPS (TTM)21.53
Shares Outstanding5,919,797
10 Day Avg. Volume8,100
30 Day Avg. Volume10,250
Financial Highlights & Ratios
PEG Ratio2.95
Price to Book (P/B)2.36
Price to Sales (P/S)3.09
P/FCF Ratio19.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and solid ROE provide durable financial flexibility. Over a multi-month horizon this supports continued R&D investment, ability to fund operations through downturns, and optionality for opportunistic M&A or capital returns without stressing liquidity or raising costly debt.
High Profit MarginsSustained high gross and net margins indicate structural pricing power and efficient operations in the metabolomics niche. Durable margins support reinvestment, absorb top-line shocks, and enable funding of specialized capabilities that reinforce competitive advantages over quarters to months.
Solid Cash GenerationConsistent free cash flow generation relative to earnings creates lasting operational resilience. Over 2-6 months this cash can finance working capital, capex for analytical platforms, or modest shareholder returns while maintaining low leverage and supporting strategic investments.
Bears Say
Declining RevenueMaterial negative revenue growth signals weakening top-line traction in the core metabolomics services market. Persistent or recurrent revenue decline erodes scale benefits, stresses margin sustainability, and limits ability to expand R&D or commercial footprint over the medium term.
Earnings VolatilityLarge negative EPS growth indicates earnings are volatile and potentially exposed to cyclical projects or one-off items. This reduces predictability of free cash flow and constrains strategic planning, dividend reliability, and reinvestment capacity across several quarters.
Small Niche ScaleA small headcount and narrow specialization limit diversification and scale. The firm may face slower market penetration, customer concentration risk, and higher per-client overhead, which can impair sustained revenue expansion and resilience against client loss over months.
Human Metabolome Technologies, Inc. News
6090 FAQ
What was Human Metabolome Technologies, Inc.’s price range in the past 12 months?
Human Metabolome Technologies, Inc. lowest stock price was ¥570.00 and its highest was ¥797.00 in the past 12 months.
What is Human Metabolome Technologies, Inc.’s market cap?
Human Metabolome Technologies, Inc.’s market cap is ¥3.42B.
When is Human Metabolome Technologies, Inc.’s upcoming earnings report date?
Human Metabolome Technologies, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 17 days.
How were Human Metabolome Technologies, Inc.’s earnings last quarter?
Human Metabolome Technologies, Inc. released its earnings results on May 13, 2026. The company reported ¥21.61 earnings per share for the quarter, beating the consensus estimate of N/A by ¥21.61.
Is Human Metabolome Technologies, Inc. overvalued?
According to Wall Street analysts Human Metabolome Technologies, Inc.’s price is currently Overvalued.
Does Human Metabolome Technologies, Inc. pay dividends?
Human Metabolome Technologies, Inc. pays a Annually dividend of ¥18 which represents an annual dividend yield of 3.12%. See more information on Human Metabolome Technologies, Inc. dividends here
What is Human Metabolome Technologies, Inc.’s EPS estimate?
Human Metabolome Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Human Metabolome Technologies, Inc. have?
Human Metabolome Technologies, Inc. has 5,919,797 shares outstanding.
What happened to Human Metabolome Technologies, Inc.’s price movement after its last earnings report?
Human Metabolome Technologies, Inc. reported an EPS of ¥21.61 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.147%.
Which hedge fund is a major shareholder of Human Metabolome Technologies, Inc.?
Currently, no hedge funds are holding shares in JP:6090
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Technical Analysis
BML
―
Shin Nippon Biomedical Laboratories, Ltd.
―
Cosmo Bio Co., Ltd.
―
―
Perseus Proteomics, Inc.
―